platoseedplatoseed
Engineering a future without cancer deaths.
Numen aims to dramatically reduce cancer deaths by deploying infrastructure and tools that enable earlier intervention. The company focuses on rapid at-home diagnostics, streamlined high-volume health data collection, and proprietary models to guide interventions for better outcomes.
Numen provides rapid at-home diagnostics, a data collection pipeline for high-volume health data, and proprietary modeling to enable earlier intervention in cancer care, all integrated to drive mortality toward zero.
Hiring/open roles; LAUNCHING SOON; based in San Francisco
Luca is an expert in network science and computational game theory. He also has a strong policy background with a focus on healthcare systems. Luca previously worked at Stockdale Street, where he gathered years of experience analyzing, investing in, and helping grow healthcare, consumer, and technology companies. He holds an MSc in Computer Science and an MSc in Global Governance from the University of Oxford where he studied as a Rhodes Scholar. Luca is a Schmidt Futures ISF Fellow.
Clinical cancer researcher with a specialty in bioinformatics, biomarkers, and methods development. Passionate about building better diagnostics and putting a dent in cancer mortality.
Combining SynBio and AI to make rapid and reliable at-home cancer testing possible
Cleancard develops a rapid at-home cancer testing platform that uses synthetic biology and AI to detect multiple cancer biomarkers from urine in 30 minutes, starting with screens for prostate, bladder, and ovarian cancers. The launch presents the product, its user base (at-home users for early detection), and the core value of faster, more sensitive, multiplexed biomarker testing without complex equipment.
From the original launch (Aug 2023) — may be outdated.
Formerly “Cleancard” · why startups rename →
We make cancer care at home possible.
Artificial intelligence for drug discovery.
